The Renal Lifecycle study was made financially possible by a historically large gift from the Piet Poortman Fund, which the Kidney Foundation received last year. In total, the Kidney Foundation is using 3.3 million euros from the gift to fund the Renal Lifecycle study. Never before has the Kidney Foundation put such a large amount into a clinical trial.
Click here for the full article on the gift the Kidney Foundation received (in Dutch).
The Australian researchers joining this research are able to do so because of a 1.6 million AUS dollar grant from the Australian government.
AstraZeneca is providing the double-blind study medication free of charge and has made 2.8 million euros available to Germany. In addition, the company provided 0.3 million euros to Spain for participation.
Singapore received a grant of 1.6 million euros from its government to take part in the study.